Edition:
United Kingdom

Resmed Inc (RMD.N)

RMD.N on New York Stock Exchange

88.06USD
5:42pm GMT
Change (% chg)

$0.28 (+0.32%)
Prev Close
$87.78
Open
$88.18
Day's High
$88.29
Day's Low
$87.69
Volume
24,274
Avg. Vol
190,950
52-wk High
$88.47
52-wk Low
$62.71

Select another date:

Tue, Dec 12 2017

NZ's Fisher & Paykel sues Resmed in Australia over patent dispute

New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents.

UPDATE 1-NZ's Fisher & Paykel sues Resmed in Australia over patent dispute

Dec 12 New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents.

NZ's Fisher & Paykel sues Resmed in patent dispute

Dec 12 New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents.

BRIEF-Resmed Inc elects Karen Drexler to its board of directors

* Resmed elects Karen Drexler to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Resmed updates on United Kingdom case with Fisher & Paykel​

* Ruling has no impact on Resmed's commercial operations in UK​

Fisher & Paykel says UK court rules rival Resmed's patent is invalid

WELLINGTON New Zealand's Fisher & Paykel Healthcare said on Monday that it could continue to sell its sleep apnea masks in Britain as a UK court had ruled that rival Resmed Inc's patent was invalid.

UPDATE 1-Fisher & Paykel says UK court rules rival Resmed's patent is invalid

* UK court rules Resmed's patent for mask invalid - F&P Healthcare

Fisher & Paykel says UK court rules rival Resmed's patent is invalid

WELLINGTON, Nov 13 A British court has ruled that a patent held by health appliance firm Resmed Inc for a mask that treats sleep apnea was invalid, rival firm Fisher & Paykel Healthcare said on Monday.

Select another date: